Home > Insider Trading > Filing (0001209191-20-001233)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178879	Amicus Therapeutics Inc.	FOLD	Pharmaceutical Preparations (2834)	200422823

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1601896	Jay Barth	C/O Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury NJ 08512	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-12-31	10,826	$9.74	137,674	No	4	F	Direct
Common Stock	Acquisiton	2020-01-02	61,601	$0.00	199,275	No	4	A	Direct
Common Stock	Disposition	2020-01-02	9,753	$9.55	189,522	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (right to buy)	Acquisiton	2020-01-02	96,818	$0.00	96,818	$9.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
96,818		2030-01-02	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	20	Indirect	By Daughter

Footnotes

Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
The Restricted Stock Units will vest in four equal annual installments beginning on January 2, 2021.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.50 to $9.61 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on the first anniversary of the grant date. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments beginning on the first month thereafter.